Peptide record

TPDB91236

C2Triazole ACE inhibitors Anticancer Antioxidant standard
6 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91236
C2Triazole
ACE inhibitors Anticancer Antioxidant
Cardiometabolic peptides Cancer-related peptides Functional / health-promoting peptides
Peptipedia CancerPPD 2.0 dbACP AnOxPePred - 1.0 AODB AoXpDb Multi-AOP
standard
No
A 6-aa standard natural multi-activity (ACE inhibitors, Anticancer, and Antioxidant) peptide sequence curated from Peptipedia, CancerPPD 2.0, dbACP, and other sources, with an available 3D structural model.
N-terminal: 4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid
Sequence
GEGSGA
Physicochemical Analysis
C17H28N6O10
RNDCQHILKMFPTWYV
G
476.44
3.29
0
1
1
-1
2.01
-0.617
16.67
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
1
E
0
Q
3
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
1
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 3 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
6
C17H28N6O10
476.44
3.29
-1
2.01
-0.617
Free
L
Linear
4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

82.12 ± 0.48 inhibition % at 10 µM
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

81.22 ± 0.30 inhibition % at 10 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019
Evidence 3 Activity

Activity

92.56 ± 0.28 inhibition % at 10 µM
Anticancer

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2019